Cyberounds Logo
September 20, 2017 | LOGIN | REGISTER | HELP | 


email a friend print Bookmark and Share
Suppression of the Renin-Angiotensin-Aldosterone System
CME credit is no longer available for this conference.
Samer Ellahham, M.D. and Helmy M. Siragy, M.D.

Dr. Ellahham is Head, The Center for Heart Failure, Department of Cardiac Sciences, SKMC/Cleveland Clinic Foundation, Abu Dhabi, UAE, and Dr. Siragy is Professor of Medicine and Endocrinology, Department of Medicine, and Director, Hypertension Center, The University of Virginia, Charlottesville, Virginia, USA.

Within the past 12 months, Dr. Ellahham reports no commercial conflicts of interest and Dr. Siragy reports no commercial conflicts of interest.

Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose.


Release Date: 01/26/2009
Termination Date: 01/26/2012

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Describe the importance of blood pressure lowering for the prevention of cardiovascular complications
  • Discuss the role of the renin-angiotensin-Aldosterone system (RAS) in development of hypertension
  • Describe the mechanisms involved with different inhibitors of the RAS
  • Discuss the recent data of the blood pressure-lowering effects achieved through renin inhibition.

 
The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity